基因生物標記市場規模、佔有率和成長分析：按生物標記類型、技術、應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球基因生物標記市場價值為 45.2 億美元，預計到 2025 年將成長至 50.8 億美元，到 2033 年將成長至 128.5 億美元，在預測期（2026-2033 年）內複合年成長率為 12.32%。

全球基因生物標記市場的發展主要得益於高通量定序技術的進步和精準醫療需求的日益成長。該市場涵蓋了檢測方法開發公司、生物資訊學平台和診斷服務機構，它們透過將基因組資訊轉化為可操作的見解來支持臨床決策。隨著個人化醫療的普及，基因生物標記有助於改善患者預後，同時最大限度地減少對傳統試驗錯治療策略的依賴。法規核准和有利的保險報銷政策是關鍵趨勢，鼓勵製造商投資於檢測方法檢驗並將基因組檢測整合到臨床工作流程中。這種環境為液態生物檢體、腫瘤檢測和罕見疾病篩檢創造了巨大的成長機會，並為新興市場的檢查室自動化和數據管理創新鋪平了道路。

全球基因生物標記市場的促進因素

精準醫療中對個人化醫療的日益重視，顯著提升了對基因生物標記的需求。這些生物標記有助於識別更有可能從標靶治療中獲益的特定患者群體，同時也能降低臨床試驗的脫落率。醫療專業人員擴大利用分子譜來指導治療方法的選擇和患者後續觀察決策，這推動了對生物標記研究和診斷技術創新的投資。為了滿足這一需求，製藥公司正與診斷公司建立策略合作夥伴關係，以促進基因組研究成果順利轉化為可操作的檢測解決方案。這些因素預計將推動各個治療領域對生物標記檢測的需求成長，從而為市場創造巨大的成長機會。

全球基因生物標記市場面臨的限制因素

全球基因生物標記市場面臨許多限制因素，其中最主要的是複雜且往往模糊的監管環境。開發商和實驗室在開發和推廣基因生物標記檢測方法時，會遇到這些挑戰。這種監管不確定性延長了核准流程，需要投入更多的時間和資源來證明其臨床效用。缺乏明確的臨床效用標準，使得臨床試驗設計更加複雜，並可能阻礙商業化夥伴關係的建立。此外，眾多實驗室認證體系的存在，以及各自不同的要求和義務，也為營運帶來了挑戰，可能限制該領域企業的成長和創新潛力。

全球基因生物標記市場趨勢

全球基因生物標記市場正受到人工智慧驅動的生物標記發現技術的顯著影響，該技術顯著提高了基因組特徵識別的速度和效率。透過利用先進的機器學習演算法並整合多樣化的生物學數據，研究人員能夠快速建立假設，並在定序、表達和表觀遺傳學研究中揭示模式。這種能力不僅簡化了預測性診斷的轉換流程，也促進了計算科學專家、生命科學公司和臨床研究人員之間的合作。因此，市場對整合基因組分析結果的創新診斷工具的需求日益成長，預計這將最終在全球範圍內徹底改變臨床決策。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球基因生物標記市場規模：依生物標記類型分類

• 預測性生物標記
• 預後生物標記
• 動態物標誌物
• 替代生物標記

全球基因生物標記市場規模：依技術分類

• NGS
• PCR
• 微陣列
• 原位雜合反應

全球基因生物標記市場規模：按應用分類

• 腫瘤學
• 心血管系統
• 中樞神經系統疾病
• 感染疾病

全球基因生物標記市場規模：依最終用戶分類

• 製藥和生物技術
• 研究機構
• 臨床診斷

全球基因生物標記市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Thermo Fisher Scientific
• Illumina Inc.
• Qiagen NV
• Foundation Medicine（Roche）
• Guardant Health
• Bio-Rad Laboratories
• Tempus Labs
• Flatiron Health（Roche）
• Myriad Genetics
• Genomic Health（Exact Sciences）
• NeoGenomics Laboratories
• Personal Genome Diagnostics
• Caris Life Sciences
• Burning Rock Biotech
• Novogene Corporation
• InVitae Corporation
• GenMark Diagnostics
• Genoptix（Novartis）
• Asuragen Inc.
• Paradigm Diagnostics

結論與建議

Global Genomic Biomarker Market size was valued at USD 4.52 Billion in 2024 and is poised to grow from USD 5.08 Billion in 2025 to USD 12.85 Billion by 2033, growing at a CAGR of 12.32% during the forecast period (2026-2033).

The global genomic biomarker market is driven by advancements in high-throughput sequencing technologies and the growing demand for precision medicine. This market encompasses assay developers, bioinformatics platforms, and diagnostic services that facilitate clinical decision-making by translating genomic information into actionable insights. As personalized medicine becomes more prevalent, genomic biomarkers offer improved patient outcomes while minimizing reliance on traditional trial-and-error therapeutic strategies. Regulatory clearances and favorable reimbursement policies are pivotal trends, as they encourage manufacturers to invest in assay validation and support the integration of genomic testing into clinical workflows. This environment fosters significant growth opportunities in liquid biopsy surveillance, oncology panels, and rare disease screening, paving the way for innovations in lab automation and data management across emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Genomic Biomarker market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Genomic Biomarker Market Segments Analysis

Global genomic biomarker market is segmented by biomarker type, technology, application, end-user and region. Based on biomarker type, the market is segmented into predictive biomarkers, prognostic biomarkers, pharmacodynamic biomarkers and surrogate biomarkers. Based on technology, the market is segmented into NGS, PCR, microarray and in situ hybridization. Based on application, the market is segmented into oncology, cardiovascular, CNS disorders and infectious disease. Based on end-user, the market is segmented into pharma & biotech, research institutes and clinical diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Genomic Biomarker Market

The rising trend of precision medicine, emphasizing tailored treatments, has significantly increased the need for genomic biomarkers. These biomarkers facilitate the identification of specific patient groups that are likely to benefit from targeted therapies while simultaneously decreasing attrition rates in clinical trials. Healthcare professionals are increasingly utilizing molecular profiles to inform treatment choices and patient monitoring, thereby driving investment in both biomarker research and diagnostic innovations. In response to these demands, pharmaceutical companies are forming strategic partnerships with diagnostic firms to streamline the transition from genomic discoveries to practical testing solutions. This convergence of factors is poised to enhance demand for biomarker tests across diverse therapeutic areas, leading to substantial market growth opportunities.

Restraints in the Global Genomic Biomarker Market

The global genomic biomarker market faces significant constraints due to the intricate and often ambiguous regulatory landscape that developers and laboratories must navigate while creating and launching genomic biomarker assays. These regulatory uncertainties can prolong the approval process, requiring additional time and resources to demonstrate clinical utility. The lack of clear standards regarding clinical utility complicates the design of clinical studies and can hinder the establishment of partnerships for commercialization. Additionally, the existence of numerous laboratory accreditations, each with distinct requirements and obligations, imposes operational challenges that may restrict the growth and innovative potential of companies in this sector.

Market Trends of the Global Genomic Biomarker Market

The Global Genomic Biomarker market is significantly influenced by the rise of AI-enabled biomarker discovery, which enhances the speed and efficiency of identifying genomic signatures. By leveraging advanced machine learning algorithms and integrating diverse biological data, researchers can rapidly generate hypotheses and uncover patterns within sequencing, expression, and epigenetic studies. This capability not only streamlines the translational pipeline for developing predictive diagnostics but also fosters collaboration among computational experts, life sciences companies, and clinical researchers. As a result, the market sees a growing demand for innovative diagnostic tools that integrate genomic findings, ultimately revolutionizing clinical decision-making on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Genomic Biomarker Market Size by Biomarker Type & CAGR (2026-2033)

• Market Overview
• Predictive Biomarkers
• Prognostic Biomarkers
• Pharmacodynamic Biomarkers
• Surrogate Biomarkers

Global Genomic Biomarker Market Size by Technology & CAGR (2026-2033)

• Market Overview
• NGS
• PCR
• Microarray
• In Situ Hybridization

Global Genomic Biomarker Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Cardiovascular
• CNS Disorders
• Infectious Disease

Global Genomic Biomarker Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Pharma & Biotech
• Research Institutes
• Clinical Diagnostics

Global Genomic Biomarker Market Size & CAGR (2026-2033)

• North America (Biomarker Type, Technology, Application, End-User)
  • US
  • Canada
• Europe (Biomarker Type, Technology, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Biomarker Type, Technology, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Biomarker Type, Technology, Application, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Biomarker Type, Technology, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tempus Labs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Flatiron Health (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health (Exact Sciences)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Personal Genome Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caris Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Burning Rock Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novogene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InVitae Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenMark Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genoptix (Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asuragen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Paradigm Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations